The Delhi government has taken a strict stance against counterfeit and narcotic drugs, intensifying its monitoring of the pharmaceutical sector. Between April and October 2025, 31 medical stores had their licenses revoked, and 15 drugs were found to be substandard.
According to an official report by the Drugs Control Department under the Health and Family Welfare Department, a total of 2,405 wholesale and retail pharmaceutical firms were inspected during this period. Violations were detected in 596 cases, prompting stringent actions, including license suspension and cancellation.
In addition, 196 firms faced special actions such as license suspension or cancellation. The department also launched targeted drives against the sale of Schedule H and H1 drugs, particularly narcotics and dual-use medications, which require strict regulation and prescriptions from licensed doctors.
Over seven months, 397 drug samples were collected from the market, of which 15 were found to be “Not of Standard Quality” (NSQ). In six cases, formal FIRs were registered.
Sources indicate that the Drugs Control Department, in coordination with the Narcotics Control Bureau, is actively working to expose the black market for counterfeit cancer drugs in the capital. These measures aim to ensure public safety and maintain the integrity of the pharmaceutical supply chain in Delhi.
Discover more from SD NEWS agency
Subscribe to get the latest posts sent to your email.